Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

70.80
Delayed Data
As of Aug 26
 +1.45 / +2.09%
Today’s Change
49.96
Today|||52-Week Range
116.96
-24.79%
Year-to-Date
No recent news for Alnylam Pharmaceuticals Inc.

Today’s Trading

Previous close69.35
Today’s open69.43
Day’s range69.12 - 71.15
Volume414,638
Average volume (3 months)860,516
Market cap$6.1B
Dividend yield--
Data as of 3:59pm ET, 08/26/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-37.37%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book4.76

Competitors

 Today’s
change
Today’s
% change
SGENSeattle Genetics Inc+1.32+3.00%
TAROTaro Pharmaceutical ...+1.52+1.20%
ALKSAlkermes Plc+0.33+0.75%
UTHRUnited Therapeutics ...-1.50-1.22%
Data as of 4:02pm ET, 08/26/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)-$1.17
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs